AngioDynamics (ANGO)
(Delayed Data from NSDQ)
$7.48 USD
+0.35 (4.91%)
Updated Jul 23, 2024 04:00 PM ET
After-Market: $7.47 -0.01 (-0.13%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$7.48 USD
+0.35 (4.91%)
Updated Jul 23, 2024 04:00 PM ET
After-Market: $7.47 -0.01 (-0.13%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth A Momentum A VGM
Zacks News
Analysts Estimate AngioDynamics (ANGO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
AngioDynamics (ANGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neogen (NEOG) Q2 Earnings Miss Estimates
by Zacks Equity Research
Neogen (NEOG) delivered earnings and revenue surprises of -41.18% and 1.10%, respectively, for the quarter ended November 2021. Do the numbers hold clues to what lies ahead for the stock?
HEXO (HEXO) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
HEXO (HEXO) delivered earnings and revenue surprises of 10% and 12.36%, respectively, for the quarter ended October 2021. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Hold on to Glaukos (GKOS) Stock Now
by Zacks Equity Research
Glaukos Corporation (GKOS) continues to benefit from a robust product portfolio and solid performing iStent technology.
OPKO Health's (OPK) Arm Declares Readiness for COVID-19 Testing
by Zacks Equity Research
OPKO Health's (OPK) BioReference Laboratories announces preparedness with respect to COVID-19 testing in the advent of the Omicron Variant.
Here's Why You Should Retain DENTSPLY SIRONA (XRAY) Now
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, forex woe persists.
Quest Diagnostics' (DGX) COVID-19 Testing Demand Up in 3 Weeks
by Urmimala Biswas
According to Quest Diagnostics (DGX), as the nation is entering the holiday season, the importance of testing service is gaining more importance with regard to minimizing the risk of community exposure of COVID-19.
Cooper Companies (COO) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Cooper Companies' (COO) fiscal fourth-quarter results are likely to reflect segmental strength.
What's in Store for Patterson Companies' (PDCO) Q2 Earnings?
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal second-quarter results are likely to reflect improvement at Dental segment.
Veeva Systems (VEEV) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Veeva Systems' (VEEV) fiscal third-quarter results are likely to reflect solid show by its segments and robust product portfolio.
Here's Why You Should Retain Patterson Companies (PDCO) Stock
by Zacks Equity Research
Patterson Companies (PDCO) continues to benefit from strength in Animal Health business and dental business.
PacBio's (PACB) Collaboration to Boost Rare Disease Diagnosis
by Zacks Equity Research
PacBio's (PACB) recent partnership with ARUP Laboratories, with regard to a study, has the potential to enhance rare disease diagnosis.
Cardinal Health's (CAH) Arm Unveils Supply Automation Solution
by Zacks Equity Research
Cardinal Health's (CAH) business introduces new offering for clinical labs that can enable them to focus on patient care.
Here's Why You Should Hold on to PerkinElmer (PKI) Stock Now
by Zacks Equity Research
PerkinElmer (PKI) continues to gain momentum from a solid product portfolio and healthy margins. However, forex woes linger.
PacBio's (PACB) New Solution to Boost Public Health Protection
by Zacks Equity Research
PacBio's (PACB) newly launched end-to-end solution is likely to help in the fight against infectious diseases and bolster public health response to pathogen threats.
Veeva Systems (VEEV) Vault Quality Suite Gets Adopted by CBM
by Zacks Equity Research
Veeva Systems' (VEEV) product gets adopted by CBM. This can drive the development and delivery of groundbreaking treatments for patients.
Baxter's (BAX) $100M Investment to Strengthen Global Presence
by Zacks Equity Research
Baxter's (BAX) strategic investment to help expand the manufacturing footprint of BPS and ensure improvement in products.
Here's Why You Should Invest in West Pharmaceutical (WST) Now
by Zacks Equity Research
West Pharmaceutical (WST) continues to gain momentum on the back of strength in Proprietary Products business.
Cooper Companies' (COO) Buyout to Boost Women's Healthcare
by Zacks Equity Research
Cooper Companies' (COO) agrees to acquire Generate Life Sciences. It will be an important addition to the former's present offerings, while improving women's healthcare.
Surmodics (SRDX) Stock Loses 2.2% Despite Q4 Earnings Beat
by Zacks Equity Research
Surmodics' (SRDX) fiscal fourth-quarter results reflect benefits from segmental strength.
Shockwave Medical (SWAV) Gains 0.6% Post Q3 Earnings Beat
by Zacks Equity Research
Shockwave Medical's (SWAV) third-quarter results reflect robust revenue growth and expansion in gross margin.
Inari Medical (NARI) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Inari Medical's (NARI) third-quarter results benefit from new product launches and continued U.S. commercial expansion.
Cardinal Health (CAH) Q1 Earnings Lag, Revenues Top Estimates
by Zacks Equity Research
Although Cardinal Health (CAH) witnessed gross margin contraction in its fiscal first-quarter results, rise in revenues in both its segments is encouraging.
AMN Healthcare (AMN) Loses 13.1% Despite Q3 Earnings Beat
by Zacks Equity Research
AMN Healthcare's (AMN) robust Q3 results demonstrate its segmental strength.
Glaukos (GKOS) Gains 3.6% Despite Reporting a Loss in Q3
by Zacks Equity Research
Despite reporting third-quarter loss, Glaukos' (GKOS) results reflect a significant rise in revenues.